BioPharmSignal logoBioPharmSignal

Biotech News

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Outlook (OTLK)OutlookFinancing

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale

Related news

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

OTLKOutlook2026-08-13 01:45 EST

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

OCGNOcugen2026-05-04 20:01 EST

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

PRQRProQR Therapeutics2026-06-25 10:35 EST

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

MGTXMeiraGTx2026-04-16 11:48 EST

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

IRIXIRIDEX2026-07-20 11:00 EST

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

KPRXKiora Pharmaceuticals2026-04-07 11:00 EST

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

OCGNOcugen2026-05-05 12:12 EST

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

LENZLenz Therapeutics Inc2026-08-04 20:05 EST

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

View all latest news

Outlook

Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...

Recent company news

OTLKOutlook2026-08-14 11:15 EST

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

OTLKOutlook2026-08-13 01:45 EST

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

OTLKOutlook2026-08-12 20:01 EST

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

OTLKOutlook2026-07-24 18:40 EST

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Stock data

Close
0.65 USD
Market cap
120.89M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States